|
Indications
Cardiovascular and Metabolic Disorders
Stage of Development
Preclinical studies
Overview
Lexicon is developing monoclonal antibodies against LG842 as a potential treatment for cardiovascular and metabolic disorders such as dyslipidemia, metabolic syndrome, and hypertriglyceridemia.
Key Target
LG842 is the secreted protein angiopoietin-like 4 (Angptl4). As part of the Genome5000TM program, Lexicon scientists found that mice lacking this protein exhibited substantially reduced triglyceride and cholesterol levels.
Preclinical Status
In preclinical research, LG842 antibodies substantially reduced triglyceride and cholesterol levels. Lexicon is conducting ongoing preclinical pharmacology and antibody optimization studies, and is evaluating multiple clinical approaches for an antibody drug candidate targeting LG842.
Related Publications
Desai, U., et al. 2007. Lipid-lowering effects of anti-angiopoietin-like4 antibody recapitulate the lipid phenotype found in angiopoietin-like4 knockout mice. PNAS, 104: 11766-11771.
|
